Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Projected EPS At $2.67 For Next Quarter


Jazz Pharmaceuticals plc (NASDAQ:JAZZ) has a mean price target of $183.75 by market experts. Market leading group First Call has reached this recommendation by considering recommendations of top analysts in the industry. These experts have specified earnings of $2.67 a share for the very next quarter and $10.08 for this year.

Technical View

The technical study of Jazz Pharmaceuticals plc demonstrates that the 50-day moving average of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) stock is $135.28, and is trading $-9.24 points away or -6.83% from 50-day moving average of $135.28. It is trading $-13.64 or -9.77% away 200-day moving average of $139.68.

The 52-week high of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) was $165.15 while $108.50 is the low mark in the same period. It state Jazz Pharmaceuticals plc share price has to surge more than $-39.11 to hit 52-week high or drop +16.17% to make a 52-week mark. MA here hints at moving average.

Taking the valuation part to reach the estimation of Jazz Pharmaceuticals plc, investors apply price-to-earnings ratio, which is shortened as P/E ratio. It weighs equity price by the relative expense of the equity. Jazz Pharmaceuticals plc (NASDAQ:JAZZ) ratio came in at 22.16, after dividing current equity price by yearly earnings. Jazz Pharmaceuticals plc stock recorded a close of $126.04 in last trading session, registering a market cap of $7.63B.

The price-earnings ratio can be seen as a means of regulating the value of per dollar of earnings through the stock market. In concept, by taking the average of P/E over a period of numerous years, one could frame something of a uniform P/E ratio, which can then be understood as a benchmark and utilized to indicate whether or not a share is worth buying.

Investors estimate the Price-to-Earnings-Growth ratio to catch up with a clear view on the firm valuation. For stocks with higher PEG ratio, they are considered as sell option. The undervalued equity displays PEG ratio of 0 or 1. On contrary, the fairly valued equity has ratio of 1 and 2. Jazz Pharmaceuticals plc (NASDAQ:JAZZ) PEG ratio is at 0.69.

1 Chart Pattern Every Investor Should Know

This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...

Click Here to See This Now.

(Visited 19 times, 1 visits today)